







CROATIA

Croatian Health Insurance Fund Margaretska 3, Zagreb info@hzzo.hr Agency for Medicinal Products and Medical Devices Ksaverska cesta 4, Zagreb halmed@halmed.hr

 Pop:
 3 850 894 inhb.

 GDP pc:
 18 731 €


 VAT on MP:
 5%

 CHE pc:
 930,62 €

Pharmaceutical pricing and reimbursement policies

Agency for Medicinal Products and Medical Devices





- VAT for all medicines = 5 %
 - Wholesale margins = differentiated wholesale margin

The wholesale price of	Wholesale margin up to %
the medicine in EUR	
< 49,99	8,5
50,00 - 299,99	7,5
300,00 - 599,99	6,5
600,00 - 1.199,99	6,0
1.200,00 - 5.999,99	5,5
6.000,00 - 25.999,99	5,0
26.000,00-66.000,00	4,5

Dispended via pharmacies and spec. stores

POM

Pharmacy retail price (PRP)

=

wholesaler price+ pharmacy margin + VAT

OTC

• Out of pocket payments

Croatian Health Insurance Fund (CHIF)

Reimbursement lists for both, out-patient (POM) and in-patient sector:



A list - basic reimbursement list of medicines

B list- supplementary reimb. list including insured person's co-payment for medicines

New medicine up to 100 % max price (HALMED) Required cut down prices for generic medicines:

1st generic medicine – up to 30%

2nd generic medicine – up to 5%

3nd generic medicine – up to 5% etc.

New medicine up to 100 % max price (HALMED) Required cut down prices for biosimilars:

1st biosimilar – up to 20%

2nd biosimilar – up to 5%

3nd biosimilar - up to 5% etc.

Out-patient sector

MP (POM) on **A-list** = up to 100% covered by CHIF MP (POM) on **B-list** = part of the amount covered by CHIF + part is patient's co-payment

Payment by CHIF to pharmacies includes service charged for dispensing (pharmacy fee 1,28 € dispensing by prescription)

Internal price referencing

Medicines included on the reimbursement lists

- cluster formed at 3rd to 5th level of ATC for out patient medicine
- at 5th level of ATC for in-patient medicines

In-patient sector

Cost of medicines included in the reimbursement

Specially intended means and payments*

Particularly expensive medicines:

- medicine for rare diseases, orphans
- extremely high price of therapy (^therapy cost annual level exceeds per patient an amount greater than 3xGDP p.c. for the previous calendar year)
 - Public procurement
- * Pricing and managed entry agreements (expensive medicines separately paid to hospitals for treatment for in-patients

REIMBURSEMENT

PRICING